1204669-67-9

Basic information

• Product Name: 1,2,4-Oxadiazol-5(4H)-one, 3-[4-[(2-aminoethyl)amino]-1,2,5-oxadiazol-3-yl]-4-(3-bromo-4-fluorophenyl)-, hydrochloride (1:1)
• Synonyms: 1,2,4-Oxadiazol-5(4H)-one, 3-[4-[(2-aminoethyl)amino]-1,2,5-oxadiazol-3-yl]-4-(3-bromo-4-fluorophenyl)-, hydrochloride (1:1);3-(4-((2-aminoethyl)amino)-1,2,5-oxadiazol-3-yl)-4-(3-bromo-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one;3-(4-((2-Aminoethyl)amino)-1,2,5-oxadiazol-3-yl)-4-(3-bromo-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one hydrochloride
• CAS NO: 1204669-67-9
• Molecular Formula: C₁₂H₁₀BrFN₆O₃*ClH
• Molecular Weight: 421.6095432
• Mol File: 1204669-67-9.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,2,4-Oxadiazol-5(4H)-one, 3-[4-[(2-aminoethyl)amino]-1,2,5-oxadiazol-3-yl]-4-(3-bromo-4-fluorophenyl)-, hydrochloride (1:1)(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,4-Oxadiazol-5(4H)-one, 3-[4-[(2-aminoethyl)amino]-1,2,5-oxadiazol-3-yl]-4-(3-bromo-4-fluorophenyl)-, hydrochloride (1:1)(1204669-67-9)
• EPA Substance Registry System: 1,2,4-Oxadiazol-5(4H)-one, 3-[4-[(2-aminoethyl)amino]-1,2,5-oxadiazol-3-yl]-4-(3-bromo-4-fluorophenyl)-, hydrochloride (1:1)(1204669-67-9)

Safety Data

• Hazardous Substances Data: 1204669-67-9(Hazardous Substances Data)

Usage

General Description

1,2,4-Oxadiazol-5(4H)-one, 3-[4-[(2-aminoethyl)amino]-1,2,5-oxadiazol-3-yl]-4-(3-bromo-4-fluorophenyl)-, hydrochloride (1:1) is a complex organic compound containing bromine, fluorine, and hydrochloride elements. This chemical compound is characterized by three chemical groups: oxadiazol, a nitrogenous heterocyclic compound, an aminoethylamino group, and a bromo-fluorophenyl group, attached in a specific structural form, which could potentially contribute to its unique chemical behavior. The compound exists in a one-to-one ratio with hydrochloride, suggesting it may exist as a salt in its solid or dissolved states. The details about its physical properties, uses, toxicity, or its role in any chemical reactions are not specified, thus requiring further research or specific context.

Upstream product

• 2019140-71-5 4‐(3‐bromo‐4‐fluorophenyl)‐3‐(4‐nitro‐1,2,5‐oxadiazol‐3‐yl)‐4,5‐dihydro‐1,2,4‐oxadiazol‐5‐one 
• 656-64-4 3-bromo-4-fluoroaniline 
• 1204669-66-8 3-(4-((2-azidoethyl)amino)-1,2,5-oxadiazole-3-yl)-4-(3-bromo-4-fluorophenyl)-1,2,4-oxadiazole-5(4H)-one 
• 1204669-65-7 2-({4-[4-(3-bromo-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-yl}amino)ethyl methanesulfonate 
• 1204669-64-6 4-(3-bromo-4-fluorophenyl)-3-{4-[(2-hydroxyethyl)amino]-1,2,5-oxadiazol-3-yl}-1,2,4-oxadiazol-5(4H)-one 
• 1204669-63-5 4-(3-bromo-4-fluorophenyl)-3-{4-[(2-methoxyethyl)amino]-1,2,5-oxadiazol-3-yl}-1,2,4-oxadiazol-5(4H)-one 
• 1204669-62-4 N-(3-bromo-4-fluorophenyl)-N‘-hydroxy-4-((2-methoxyethyl)amino)-1,2,5-oxadiazole-3-carboximidamide 
• 1204669-61-3 N-hydroxy-4-[(2-methoxyethyl)amino]-1,2,5-oxadiazole-3-carboximidoyl chloride 
• 1204669-60-2 N¹-hydroxy-4-((2-methoxyethyl)amino)-1,2,5-oxadiazole-3-carboximidamide 
• 1204669-59-9 4-amino-N‘-hydroxy-N-(2-methoxyethyl)-1,2,5-oxadiazole-3-carboximidamide 
• 1204669-68-0 tert‐butyl N‐[2‐({4‐[4‐(3‐bromo‐4‐fluorophenyl)‐5‐oxo‐1,2,4‐oxadiazol‐3‐yl]‐1,2,5‐oxadiazol‐3‐yl}amino)ethyl]carbamate 

Downstream Products

• 1204669-69-1 (Ν-(2-((4-(4-(3-bromo-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,2,5-oxadiazol-3-yl)amino)ethyl)tert-butylsulfamoyl)carbamate 
• 1204669-37-3 4-({2-[(aminosulfonyl)amino]ethyl}amino)-N-(3-bromo-4-fluorophenyl)-N’-hydroxy-1,2,5-oxadiazole-3-carboximidamide 
• 1204669-70-4 N-[2-({4-[4-(3-bromo-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-yl}amino)ethyl]sulfamide 
• 1204669-37-3 (Z)-4-({2-[(aminosulfonyl)amino]ethyl}amino)-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide 

Relevant articles and documents

A kind of IDO inhibitor and use thereof

The embodiment of the invention provides general formula (I) compound or its pharmaceutically acceptable salts, stereoisomers, a tautomeric form each other, polymorphs, solvate, prodrug, metabolite or isotope derivatives, wherein the substituents R1

Discovery of phosphonamidate IDO1 inhibitors for the treatment of non-small cell lung cancer

Targeting indoleamine 2,3-dioxygenase 1 (IDO1) has been identified as an attractive approach for the development of cancer immunotherapy. In this study, a series of phosphonamidate ester containing compounds were designed, synthesized and evaluated for their inhibitory activities against IDO1. Among them, compounds 16, 17, and 26 with good IDO1 inhibitory (HeLa IDO1 IC50 = 10–21 nM, hIDO1 IC50 = 78–121 nM) activities were selected for further investigation and showed good physicochemical properties. Furthermore, based on comparable PK profile and excellent IDO2/TDO inhibitory potency, representative compound 16 was selected for further bio-evaluation and characterized with good efficacy in suppressing lung metastasis (77% inhibition rate) of Lewis cells in vivo. Thus, compound 16 could be a potential and efficacious agent for further evaluation.

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology

A data-centric medicinal chemistry approach led to the invention of a potent and selective IDO1 inhibitor 4f, INCB24360 (epacadostat). The molecular structure of INCB24360 contains several previously unknown or underutilized functional groups in drug subs